Namodenoson not checked
Can-Fite BioPharma · CF102
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 3
- “This is a clinical trial in patients with advanced hepatocellular carcinoma (HCC) and Child-Pugh Class B7 (CPB7) cirrhosis whose disease has progressed on at least 1st-line therapy. The trial will evaluate the efficacy and safety of namodenoson as compared to placebo.”In the company’s words, NCT05201404 on ClinicalTrials.gov
- Other names
- CF102 · IB-MECA · Cl-IB-MECA
Other drugs for Hepatocellular Carcinoma
- CadonilimabAkeso · Phase 3
- DurvalumabAstraZeneca · Phase 3
- TremelimumabAstraZeneca · Phase 3
- BudigalimabAbbVie · Phase 2/3
- LivmoniplimabAbbVie · Phase 2/3
- BGB-B2033BeOne Medicines (BeiGene) · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Feb 2026 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis | |
| Phase 2Recruiting | 15 Jul 2026 | Namodenoson Treatment of Advanced Pancreatic Cancer | |
| Phase 2Completed | 27 Nov 2017 | Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC) | |
| Phase 2Unknown | 15 Apr 2025 | Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH) | |
| Phase 1/2Completed | Dec 2012 | A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026